Availability of generic drugs can impact prescription prices dramatically, but supply challenges and questions about profitability may hinder those savings.
Seemingly intractable drug shortages have spawned Civica Rx, which maps out a phased approach to bringing more generic drugs to market.
The Medicaid and CHIP Payment and Access Commission is slated to meet to review recommendations on disproportionate-share hospital allotments, upper payment limit compliance, measuring program integrity and more.
The middlemen of group purchasing organizations and pharmacy benefit managers remain a central part of the drug pricing and shortage debate.
This week the House committee chairs finalized their subcommittees and figured out who will be leading the healthcare policy charge in the lower chamber for the 116th Congress.
HHS Secretary Alex Azar said a proposal to tie prices for certain Medicare drugs to lower prices paid overseas is already paying dividends even though it hasn't formally been introduced yet.
Pharma critic Rep. Elijah Cummings is probing a dozen manufacturers over their drug pricing strategies and a bipartisan duo is calling for the FTC and Justice Department to come down on Bristol-Myers Squibb's acquisition of Celgene.
UnitedHealthcare will give 10,000 opioid disposal kits to Recovery Point West Virginia to give to people so they can remove the drugs from their homes.
340B proponents feel Democratic control of the House may have pivoted the conversation toward adding reporting and transparency requirements and away from cutting reimbursement.
The Trump administration continues its verbal assault on high drug prices, and more-concrete regulatory action is expected this year.
The Food and Drug Administration found an Akorn facility violated current good manufacturing practice regulations. The drugmaker's stock has taken a hit due to the warning letter.
New Democratic Gov. Gavin Newsom of California wants the state to fund more subsidies for Obamacare and negotiate prices with drugmakers.